Abstract
Antimicrobial susceptibility testing (AST) remains the cornerstone of effective antimicrobial selection and optimization in patients. Despite recent advances in rapid pathogen identification and resistance marker detection with molecular diagnostics, phenotypic AST methods remain relatively unchanged over the last few decades. Guided by the principles of microfluidics, we describe the application of a multi-liquid-phase microfluidic system, named under-oil open microfluidic systems (UOMS) to achieve a rapid phenotypic AST. UOMS provides a next-generation solution for AST (UOMS-AST) by implementing and recording a pathogen antimicrobial activity in micro-volume testing units under an oil overlay with label-free, single-cell resolution optical access. UOMS-AST can accurately and rapidly determine antimicrobial activity from nominal sample/bacterial cells in a system aligned with clinical laboratory standards. Further, we combine UOMS-AST with cloud lab data analytic techniques for real-time image analysis and report generation to provide a rapid (i.e., <4 h) sample-to-answer turnaround time, shedding light on its utility as a next-generation phenotypic AST platform for clinical application.
Competing Interest Statement
D.J.B. holds equity in BellBrook Labs LLC, Tasso Inc. Stacks to the Future LLC, Lynx Biosciences LLC, Onexio Biosystems LLC, Turba LLC, Flambeau Diagnostics LLC, and Salus Discovery LLC. The remaining authors declare no competing financial interests.
Funding Statement
NSF EFRI-1136903-EFRI-MKS, NIH R01 CA247479, NIH R01 AI154940, NIH R01 EB010039, NIH R01 CA185251, NIH R01 CA186134, NIH R01 CA181648, NIH R01AI132627, NIH P30CA014520, EPA H-MAP 83573701, and American Cancer Society IRG-15-213-51.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵✉ e-mail: cli479{at}wisc.edu; warren.rose{at}wisc.edu; djbeebe{at}wisc.edu
Data Availability
All study data are included in the article and/or supporting information. The data that support the findings of this study are available from the corresponding authors upon reasonable request.
